Endear Life Science Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 20-12-2024
- Paid Up Capital ₹ 1.42 M
as on 20-12-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -4.06%
(FY 2021)
- Profit 23.16%
(FY 2021)
- Ebitda 204.14%
(FY 2021)
- Net Worth 17.78%
(FY 2021)
- Total Assets -12.90%
(FY 2021)
About Endear Life Science
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.42 M, as per Ministry of Corporate Affairs (MCA) records.
Anjali Singh, Anjali Singh, Ravi Suman, and One other member serve as directors at the Company.
- CIN/LLPIN
U24297BR2011PTC016944
- Company No.
016944
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 May 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Endear Life Science?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajiv Singh  | Managing Director | 09-May-2011 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Anjali Singh | Director | 15-Nov-2011 | Current |
| Ravi Suman | Director | 09-May-2011 | Current |
Financial Performance of Endear Life Science.
Endear Life Science Private Limited, for the financial year ended 2021, experienced Minor drop in revenue, with a 4.06% decrease. The company also saw a substantial improvement in profitability, with a 23.16% increase in profit. The company's net worth Soared by an impressive increase of 17.78%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Endear Life Science?
In 2021, Endear Life Science had a promoter holding of 81.63% and a public holding of 18.37%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Toss-Up Pharmaceuticals Private LimitedActive 4 years 26 daysRavi Suman and Rajiv Singh are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Endear Life Science?
Endear Life Science has a workforce of 3 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Endear Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Endear Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
